MiMedx Selling General Administrative from 2010 to 2024

MDXG Stock  USD 9.16  0.28  2.97%   
MiMedx's Selling General Administrative is increasing over the last several years with slightly volatile swings. Selling General Administrative is predicted to flatten to about 123.2 M. During the period from 2010 to 2024 MiMedx Group Selling General Administrative regressed destribution of quarterly values had coefficient of variationof  62.47 and r-value of  0.76. View All Fundamentals
 
Selling General Administrative  
First Reported
2008-03-31
Previous Quarter
55.4 M
Current Value
53.5 M
Quarterly Volatility
1.1 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MiMedx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MiMedx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 6.8 M or Selling General Administrative of 123.2 M, as well as many indicators such as Price To Sales Ratio of 3.02, Dividend Yield of 0.0 or PTB Ratio of 6.8. MiMedx financial statements analysis is a perfect complement when working with MiMedx Valuation or Volatility modules.
  
Check out the analysis of MiMedx Correlation against competitors.

Latest MiMedx's Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of MiMedx Group over the last few years. It is MiMedx's Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MiMedx's overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
216.252.181.198.208.206.123.-1%-40%
       Timeline  

MiMedx Selling General Administrative Regression Statistics

Arithmetic Mean140,767,959
Geometric Mean79,916,568
Coefficient Of Variation62.47
Mean Deviation74,684,977
Median170,112,000
Standard Deviation87,936,193
Sample Variance7732.8T
Range252M
R-Value0.76
Mean Square Error3539.9T
R-Squared0.57
Significance0
Slope14,909,314
Total Sum of Squares108258.8T

MiMedx Selling General Administrative History

2024123.2 M
2023206.7 M
2022208.8 M
2021198.4 M
2020181 M
2018252.6 M
2017216 M

About MiMedx Financial Statements

MiMedx stakeholders use historical fundamental indicators, such as MiMedx's Selling General Administrative, to determine how well the company is positioned to perform in the future. Although MiMedx investors may analyze each financial statement separately, they are all interrelated. For example, changes in MiMedx's assets and liabilities are reflected in the revenues and expenses on MiMedx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MiMedx Group. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative206.7 M123.2 M

Currently Active Assets on Macroaxis

When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:
Check out the analysis of MiMedx Correlation against competitors.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.1)
Earnings Share
0.59
Revenue Per Share
2.447
Quarterly Revenue Growth
0.029
Return On Assets
0.1838
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…